RecruitingNot ApplicableNCT07056959

Efficacy of Collagen Matrix for Peri-implant Soft Tissue Phenotype Modification

Efficacy of Collagen Matrix for Peri-implant Soft Tissue Phenotype Modification: A Randomized Controlled Trial


Sponsor

Mohammed Bin Rashid University of Medicine and Health Sciences

Enrollment

30 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

A stable band of keratinized mucosa (KM) around dental implants is thought to minimize tissue recession and provide resistance against mechanical, chemical, and microbial challenges, thereby preserving peri-implant tissue health. Soft tissue augmentation is often employed to enhance the soft tissue phenotype in such cases. While autogenous grafts such as free gingival grafts (FGG) remain the gold standard, xenogeneic collagen matrices (XCM) have emerged as promising alternatives, offering reduced patient morbidity and surgical time. This randomized controlled clinical trial aims to compare the clinical efficacy and patient-reported outcome measures (PROMs) of XCM versus FGG for soft tissue phenotype modification when performed during healing abutment connection around dental implants, with evaluations at both short-term (6 months) and long-term (1 and 2 years) intervals. Thirty participants will be recruited at Dubai Health Dental Hospital and randomly assigned to receive either XCM (test) or FGG (control) augmentation. Clinical assessments will be conducted at baseline (T0), 2 weeks (T2w), and at 1 (T1), 3 (T3), 6 (T6), 12 (T12), and 24 (T24) months post-surgery. The primary outcome is the change in KM width, measured from the mucosal margin to the mucogingival junction. Secondary outcomes include KM thickness, supracrestal tissue height, and soft tissue dimensional changes, assessed using intraoral scans (Trios 5) and superimposed STL files. Additional measurements include peri-implant soft tissue level and phenotype. PROMs will be recorded in the first postoperative week and at the 3-year mark using a visual analog scale (VAS). Clinical indices such as plaque index, bleeding index, and probing depth will be evaluated at 6 months, 1 year, and 2 years. Marginal bone level changes and implant survival rates will also be tracked throughout the study period.


Eligibility

Min Age: 21 Years

Inclusion Criteria5

  • Aged 21 or over.
  • Insufficient KM width (\< 2 mm) at the buccal aspect of implants at time of healing abutment placement, either for single anterior or posterior implants.
  • Controlled oral hygiene (full-mouth plaque and bleeding scores ≤ 25% at baseline).
  • Good compliance and commitment to attend follow-up review appointments.
  • Willing to provide informed consent.

Exclusion Criteria7

  • Smoking
  • Untreated localized or generalized periodontal diseases
  • Uncontrolled systemic diseases
  • Long term use of non-steroidal anti-inflammatory medications
  • History of malignancy, radiotherapy or chemotherapy
  • Collagen allergy
  • History of mucogingival surgery

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESoft tissue substitute for peri-implant phenotype modification

XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when

PROCEDUREControl Group - Free gingival graft for soft tissue augmentation

Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification


Locations(1)

Dubai Dental Hospital

Dubai, United Arab Emirates

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07056959


Related Trials